Current Report Filing (8-k)
February 23 2017 - 5:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 22, 2017
CELGENE CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34912
|
22-2711928
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
86 Morris Avenue, Summit, New Jersey
|
|
07901
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
|
|
Registrant’s telephone number, including
area code: (908) 673-9000
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
ITEM 5.02
|
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS
OF CERTAIN OFFICERS.
|
Celgene Corporation (the “Company”) today announced
organizational changes. Jacqualyn Fouse, PhD, has announced her retirement as an officer of the Company effective June 30, 2017
and will not stand for reelection to the Board of Directors at the upcoming Annual Meeting in June. Additionally, effective April
1, 2017:
-
Scott Smith, President, Global Inflammation & Immunology, will be promoted to President and Chief
Operating Officer.
-
Terrie Curran will be promoted to President, Global Inflammation & Immunology.
A copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
(d) Exhibit 99.1 Press Release dated
February 23, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELGENE CORPORATION
|
|
|
|
Date: February 23, 2017
|
By:
|
/s/ Peter
N. Kellogg
|
|
|
Peter N. Kellogg
Executive Vice President
Chief Financial Officer
(principal financial and accounting
officer)
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release dated February 23, 2017 announcing certain management changes.
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024